Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma

NCT01234935 is registered in ClinicalTrials.gov with Translational Oncology Research International as lead sponsor.

NCT NCT01234935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01234935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma
Lead sponsor
Translational Oncology Research International
Phase
Phase 2
Overall status
Completed
Start date
January 13, 2011
Completion date
November 27, 2017
Enrollment
8 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acinar cell adenocarcinoma of the pancreas, duct cell adenocarcinoma of the pancreas, recurrent pancreatic cancer, stage ia pancreatic cancer, stage ib pancreatic cancer, stage iia pancreatic cancer, stage iib pancreatic cancer, stage iii pancreatic cancer